{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:00:26Z","timestamp":1791252026846,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier","isbn-type":[{"value":"9780128203231","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.podrm.2019.10.006","type":"book-chapter","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T18:36:59Z","timestamp":1576175819000},"page":"159-197","source":"Crossref","is-referenced-by-count":69,"title":["Meloxicam"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.podrm.2019.10.006_bib1","series-title":"United States Pharmacopoeia\u201438 National Formulary 33","first-page":"4231","author":"The United States Pharmacopoeial Convention","year":"2015"},{"key":"10.1016\/bs.podrm.2019.10.006_bib2","series-title":"British Pharmacopoeia. vol. II","first-page":"2373","year":"2016"},{"key":"10.1016\/bs.podrm.2019.10.006_bib3","unstructured":"Website: http:\/\/rxisk.org\/drug\/1680\/Meloxicam\/111644\/Melcox(KR)\/#Brand_names. (Accessed May 2016)."},{"key":"10.1016\/bs.podrm.2019.10.006_bib4","unstructured":"Website: https:\/\/www.rsc.org\/MerckIndex\/monograph\/m7164\/meloxicam?q=unauthorize. (Accessed May 2016)."},{"key":"10.1016\/bs.podrm.2019.10.006_bib5","series-title":"Martindale: The Complete Drug Reference","first-page":"80","year":"2009"},{"key":"10.1016\/bs.podrm.2019.10.006_bib6","series-title":"Rescaldina","author":"Vigano","year":"2006"},{"key":"10.1016\/bs.podrm.2019.10.006_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jlcr.1261","article-title":"Synthesis of deuterium-labelled meloxicam and piroxicam","volume":"50","author":"Balssa","year":"2007","journal-title":"J. Label. Comp. Radiopharm."},{"issue":"11","key":"10.1016\/bs.podrm.2019.10.006_bib8","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.5012\/bkcs.2005.26.11.1771","article-title":"An efficient synthesis of 2-Alkyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides","volume":"26","author":"Rehman","year":"2005","journal-title":"Bull. Korean Chem. Soc."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1590\/S1984-82502009000100008","article-title":"Dissolution test optimization for meloxicam in the tablet pharmaceutical form","volume":"45","author":"Oliveira","year":"2009","journal-title":"Braz. J. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2019.10.006_bib10","series-title":"Clarke's Analysis of Drugs and Poisons","first-page":"1618","year":"2011"},{"key":"10.1016\/bs.podrm.2019.10.006_bib11","series-title":"1st Annual International Interdisciplinary Conference","first-page":"779","article-title":"Solid lipid nanoparticles for topical delivery of meloxicam: development and in vitro characterization","author":"Khalil","year":"2013"},{"key":"10.1016\/bs.podrm.2019.10.006_bib12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/s6091139","article-title":"Voltammetric determination of meloxicam in pharmaceutical formulation and human serum at glassy carbon electrode modified by cysteic acid formed by electrochemical oxidation of L-cysteine","volume":"6","author":"Wang","year":"2006","journal-title":"Sensors"},{"issue":"5","key":"10.1016\/bs.podrm.2019.10.006_bib13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1081\/AL-100103216","article-title":"Electrochemical oxidation of meloxicam and its determination in tablet dosage form","volume":"34","author":"Radi","year":"2001","journal-title":"Anal. Lett."},{"issue":"5","key":"10.1016\/bs.podrm.2019.10.006_bib14","first-page":"329","article-title":"Electrochemical studies using activated glassy carbon (meloxicam)","volume":"55","author":"cristian","year":"2010","journal-title":"Roum. Chim."},{"key":"10.1016\/bs.podrm.2019.10.006_bib15","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1039\/C4AY02034K","article-title":"Determination of meloxicam in plasma samples using a highly selective and sensitive voltammetric sensor based on carbon paste electrodes modified by molecularly imprinted polymer nanoparticle\u2013multiwall carbon nanotubes","volume":"7","author":"Deilami","year":"2015","journal-title":"Anal. Methods"},{"key":"10.1016\/bs.podrm.2019.10.006_bib16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0014-827X(02)01239-9","article-title":"Polarographic behaviour of meloxicam and its determination in tablet preparations and spiked plasma","volume":"57","author":"Alt\u0131noz","year":"2002","journal-title":"Il Farmaco"},{"issue":"10","key":"10.1016\/bs.podrm.2019.10.006_bib17","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1248\/cpb.49.1257","article-title":"Cathodic adsorptive stripping square-wave voltammetry of the anti-inflammatory drug meloxicam","volume":"49","author":"Radi","year":"2001","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/bs.podrm.2019.10.006_bib18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0731-7085(01)00528-3","article-title":"Electrochemical reduction of meloxicam at mercury electrode and its determination in tablets","volume":"27","author":"Beltagi","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2019.10.006_bib19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0731-7085(01)00530-1","article-title":"Spectrophotometric and fluorimetric methods for the determination of meloxicam in dosage forms","volume":"27","author":"Hassan","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"10","key":"10.1016\/bs.podrm.2019.10.006_bib20","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1080\/00032719908542951","article-title":"Determination of meloxicam in tablet formulations by ultraviolet spectrophotometry and high-performance liquid chromatography","volume":"32","author":"Charles","year":"1999","journal-title":"Anal. Lett."},{"issue":"4","key":"10.1016\/bs.podrm.2019.10.006_bib21","first-page":"217","article-title":"Spectrophotometric estimation of meloxicam in bulk and its pharmaceutical formulations","volume":"1","author":"Dhandapani","year":"2010","journal-title":"Int. J. Pharma Sci. Res."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib22","first-page":"13","article-title":"Validated determination of meloxicam in tablets by using UV spectrophotometry","volume":"24","author":"Nemutlu","year":"2004","journal-title":"J. Fac. Pharm."},{"issue":"12","key":"10.1016\/bs.podrm.2019.10.006_bib23","first-page":"963","article-title":"Spectrophotometric method for determination of meloxicam in pharmaceutical formulations using N-bromosuccinimide as an oxidant","volume":"5","author":"Hasan","year":"2014","journal-title":"Int. J. Pharma Sci. Res."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib24","first-page":"1","article-title":"Development of new colorimetric method and validation for determination of meloxicam in bulk and marketed formulation","volume":"2","author":"Kashyap","year":"2013","journal-title":"Int. J. Pharm. Arch."},{"issue":"3","key":"10.1016\/bs.podrm.2019.10.006_bib25","first-page":"315","article-title":"A turbidimetric method for\u00a0the assay of meloxicam using molybdophosphoric acid","volume":"58","author":"Murarasu","year":"2010","journal-title":"Farmacia"},{"key":"10.1016\/bs.podrm.2019.10.006_bib26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/bio.1117","article-title":"Flow-injection analysis for meloxicam based on tris(2,2\u2032-bipyridine) ruthenium (II)\u2013Ce (IV) chemiluminescent system","volume":"24","author":"Ye","year":"2009","journal-title":"Luminescence"},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib27","article-title":"Determination of meloxicam by synchronous scanning fluorometric method,","volume":"13","author":"Zhen","year":"2007","journal-title":"Anal. Test. Technol. Instrum."},{"key":"10.1016\/bs.podrm.2019.10.006_bib28","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1039\/C4AY00809J","article-title":"A rapid and highly sensitive fluorimetric method for the determination of meloxicam using uranyl acetate","volume":"6","author":"Tian","year":"2014","journal-title":"Anal. Methods"},{"key":"10.1016\/bs.podrm.2019.10.006_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0731-7085(02)00641-6","article-title":"Method development and validation for the analysis of meloxicam in tablets by CZE","volume":"31","author":"Nemutlu","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2019.10.006_bib30","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/jssc.200500412","article-title":"Simultaneous determination of celecoxib, meloxicam, and rofecoxib using capillary electrophoresis with surfactant and application in drug formulations","volume":"29","author":"Hsieh","year":"2006","journal-title":"J. Sep. Sci."},{"issue":"9","key":"10.1016\/bs.podrm.2019.10.006_bib31","first-page":"273","article-title":"Development of a reversed phase HPLC method for determination of meloxicam in tablet formulation and human serum","volume":"11","author":"Hasan","year":"2015","journal-title":"Eur. Sci. J."},{"key":"10.1016\/bs.podrm.2019.10.006_bib32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0378-4347(99)00537-X","article-title":"Development and validation of a new high-performance liquid chromatographic estimation method of meloxicam in biological samples","volume":"738","author":"Velpandian","year":"2000","journal-title":"J. Chromatogr. B"},{"issue":"4","key":"10.1016\/bs.podrm.2019.10.006_bib33","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2478\/s11696-010-0031-9","article-title":"Liquid chromatographic determination of meloxicam in serum after solid phase extraction","volume":"64","author":"Ouarezki","year":"2010","journal-title":"Chem. Pap."},{"issue":"4","key":"10.1016\/bs.podrm.2019.10.006_bib34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2478\/amma-2014-0031","article-title":"Development of a HPLC-UV method for determination of meloxicam in human plasma and pharmaceutical dosage forms","volume":"60","author":"Enik\u0151","year":"2014","journal-title":"Acta Med. Marisiensis"},{"issue":"5","key":"10.1016\/bs.podrm.2019.10.006_bib35","first-page":"679","article-title":"Development and validation of assay method for\u00a0meloxicam tablets by RP-HPLC","volume":"1","author":"Ranjith","year":"2013","journal-title":"Indian J. Res. Pharm. Biotechnol."},{"issue":"4","key":"10.1016\/bs.podrm.2019.10.006_bib36","first-page":"1051","article-title":"A validated RP-HPLC method for determination of Meloxicam in the Presence of its Impurities","volume":"1","author":"Sinha","year":"2009","journal-title":"Int. J. Pharm. Tech. Res."},{"issue":"95","key":"10.1016\/bs.podrm.2019.10.006_bib37","article-title":"Validation of assay indicating method development of meloxicam in bulk and some of its tablet dosage forms by RP-HPLC","volume":"3","author":"Sahoo","year":"2014","journal-title":"Springer Plus"},{"key":"10.1016\/bs.podrm.2019.10.006_bib38","first-page":"7","article-title":"High-performance liquid chromatography determination of meloxicam and piroxicam with ultraviolet detection","volume":"2014","author":"Cox","year":"2014","journal-title":"Chromatogr. Res. Int."},{"key":"10.1016\/bs.podrm.2019.10.006_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jchromb.2007.09.004","article-title":"Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study","volume":"859","author":"Bae","year":"2007","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/bs.podrm.2019.10.006_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jpba.2007.09.011","article-title":"Method development and validation for the simultaneous determination of meloxicam and pridinol mesylate using RP-HPLC and its application in drug formulations","volume":"46","author":"Vignaduzzo","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib41","first-page":"58","article-title":"A new RP-HPLC method for analysis of meloxicam in tablets","volume":"18","author":"arayne","year":"2005","journal-title":"Pak. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib42","first-page":"152","article-title":"Development and validation of a reverse phase-HPLC method for determination of meloxicam in pharmaceutical dosage forms and human plasma","volume":"12","author":"Shaji","year":"2012","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"issue":"53","key":"10.1016\/bs.podrm.2019.10.006_bib43","first-page":"21","article-title":"Optimization and validation of RP-HPLC method for the estimation of meloxicam and paracetamol with its genotoxic impurity (p-amino phenol) in bulk and pharmaceutical drug product using PDA detector","volume":"6","author":"Soni","year":"2016","journal-title":"Asian J. Biomed. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2019.10.006_bib44","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0731-7085(02)00064-X","article-title":"LC determination and pharmacokinetics of meloxicam","volume":"28","author":"Dasandi","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"7","key":"10.1016\/bs.podrm.2019.10.006_bib45","first-page":"545","article-title":"Validated RP-HPLC method for simultaneous estimation of meloxicam and amoxicillin sodium in bulk and combined dosage form","volume":"3","author":"Shaik","year":"2014","journal-title":"World J. Pharm. Res."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib46","first-page":"1","article-title":"Potentiometric and HPLC methods for the determination of meloxicam in bulk and drug formulations","volume":"2","author":"El-Ries","year":"2010","journal-title":"Insight Pharm. Sci."},{"issue":"3","key":"10.1016\/bs.podrm.2019.10.006_bib47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4314\/tjpr.v8i3.44543","article-title":"A stability indicating HPLC method for the determination of meloxicam in bulk and commercial formulations","volume":"8","author":"Bandarkar","year":"2009","journal-title":"Trop. J. Pharm. Res."},{"issue":"5","key":"10.1016\/bs.podrm.2019.10.006_bib48","first-page":"33","article-title":"Method development and validation of a stability indicating RP-HPLC method for analysis of meloxicam using dad detector","volume":"1","author":"Wali","year":"2013","journal-title":"Acta Pol. Pharm. Res. Dev."},{"issue":"2","key":"10.1016\/bs.podrm.2019.10.006_bib49","first-page":"225","article-title":"TLC determination of meloxicam in tablets and after acidic and alkaline hydrolysis","volume":"69","author":"Starek","year":"2012","journal-title":"Acta Pol. Pharm. Res."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib50","first-page":"160","article-title":"Development of a validated stability-indicating HPTLC method for determination of meloxicam in bulk and pharmaceutical formulations: pertinence to ICH guidelines","volume":"4","author":"Shaji","year":"2012","journal-title":"Int. J. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2019.10.006_bib51","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jchromb.2007.01.036","article-title":"Determination of meloxicam in human plasma by liquid chromatography\u2013tandem mass spectrometry following transdermal administration","volume":"852","author":"Yuan","year":"2007","journal-title":"J. Chromatogr. B"},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4155\/bio.09.10","article-title":"Liquid chromatography\u2013tandem mass spectrometry method for the determination of meloxicam and its metabolite 5-carboxymeloxicam in human plasma","volume":"1","author":"Lee","year":"2009","journal-title":"Bioanalysis"},{"key":"10.1016\/bs.podrm.2019.10.006_bib53","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/10826076.2012.678453","article-title":"Estimation of meloxicam in human plasma by liquid chromatography-tandem mass spectrometry (LC-MS\/MS)","volume":"36","author":"Ganesh","year":"2013","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/rheumatology\/35.suppl_1.13","article-title":"A review of the clinical pharmacokinetics of meloxicam","volume":"35","author":"Turck","year":"1996","journal-title":"Br. J. Rheumatol."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/004982598239704","article-title":"Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4","volume":"28","author":"Chesn\u00e9","year":"1998","journal-title":"Xenobiotica"},{"key":"10.1016\/bs.podrm.2019.10.006_bib56","series-title":"Mobic\u00ae (Meloxicam) Tablets Prescribing Information","author":"Boehringer Ingelheim","year":"2006"},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.006_bib57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/rheumatology\/35.suppl_1.4","article-title":"Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2","volume":"35","author":"Engelhardt","year":"1996","journal-title":"Br. J. Rheumatol."},{"issue":"10","key":"10.1016\/bs.podrm.2019.10.006_bib58","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF01757699","article-title":"Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favorable gastrointestinal tolerance","volume":"44","author":"Engelhardt","year":"1995","journal-title":"Inflamm. Res."}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology","Profiles of Drug Substances, Excipients, and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512519300214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512519300214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:34:12Z","timestamp":1761730452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512519300214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128203231"],"references-count":58,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2019.10.006","relation":{},"ISSN":["1871-5125"],"issn-type":[{"value":"1871-5125","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}